Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14515278 | 0.95 | CYP3A4 (0.61) | CYP3A4CYP2D6 | |
| SCHEMBL8229159 | 0.90 | CYP3A4 (0.64) | CYP3A4CYP2D6 | |
| SCHEMBL8229241 | 0.90 | CYP3A4 (0.68) | CYP3A4CYP2D6 | |
| SCHEMBL14515307 | 0.88 | CYP3A4 (0.82) | CYP3A4CYP2D6 | |
| SCHEMBL8229721 | 0.85 | CYP3A4 (0.68) | CYP3A4CYP2D6 | |
| SCHEMBL8229149 | 0.84 | CYP3A4 (0.56) | CYP3A4CYP2D6 | |
| SCHEMBL8229155 | 0.84 | CYP3A4 (0.53) | CYP3A4CYP2D6 | |
| SCHEMBL8229148 | 0.82 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| SCHEMBL8223680 | 0.82 | CYP3A4 (0.74) | CYP3A4CYP2D6 | |
| SCHEMBL8229212 | 0.81 | CYP3A4 (0.52) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-7220735-B2 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220735-B2 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | CYP3A4 1140/4885CYP2D6 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.